JOHN W. KOZARICH - 11 May 2021 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Charles S. Berkman For: John W. Kozarich
Issuer symbol
LGND
Transactions as of
11 May 2021
Net transactions value
-$1,337
Form type
4
Filing time
13 May 2021, 20:57:13 UTC
Next filing
07 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $48,930 +4,835 +16% $10.12* 34,543 11 May 2021 Direct
transaction LGND Common Stock Tax liability $50,267 -391 -1.1% $128.56 34,152 11 May 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -4,835 -100% $0.000000* 0 11 May 2021 Common Stock 4,835 $10.12 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer in payment of the exercise price of options.
F2 Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date.